UA128403U - METHOD OF FORECASTING OSTEOARTHrosis DEVELOPMENT - Google Patents

Abstract

A method for predicting the development of osteoarthritis includes clinical examination, radiography. Determine in serum the polymorphism of the nitric oxide synthase gene (eNOS T786C) and the content of thrombomodulin, C-terminal collagen type I propeptide (SICP), homocysteine, C-reactive protein (SRP), which at homozygous level of carrier 5 ng / ml, CISR <102 ng / ml, homocysteine> 20 μmol / l, SRP> 6 mg / l predict the development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, examination of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N. Okorokov. Diagnostics of diseases of internal organs. M., 2001. - vol. 2. - pp. 186-196).

The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (eMmoO5 17786C), the content of thrombomodulin, C-terminal propeptide of collagen type I (SICP), homocysteine, C-reactive protein (CRP) is determined in the patient's blood serum ) and with homozygous carrier 786-SS, levels of thrombomodulin "5 ng/ml, SSRI "102 ng/ml, homocysteine 220 μmol/l, SRP "6 mg/l predict the development of osteoarthritis.

Application of the method. Upon admission, the patient is examined, an X-ray is taken, the polymorphism of the eMmo5 T786C gene is determined, the content of thrombomodulin is determined by the immunoenzymatic method,

SISR, homocysteine, SRP. With homozygous carrier 786-SS and levels of thrombomodulin "5 ng/ml, SICR "102 ng/ml, homocysteine 220 μmol/l, SRP "b mg/l predict the development of osteoarthritis.

A specific example of using the method.

Patient V., 56 years old, was admitted to the clinic due to pain in the left hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. The eMMO5 gene polymorphism T786C was determined in blood serum, and the content of thrombomodulin, SICP, homocysteine, and SRP was determined by the immunoenzymatic method. A homozygous carrier of 786-SS was established, thrombomodulin levels - 14.5 ng/ml, SICP - 85 ng/ml, homocysteine - 28 μmol/l, PSA - 14 mg/l.

The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (MOB T786C) and the content of thrombomodulin, C-terminal propeptide of type I collagen (SICP), homocysteine, C-reactive protein (SRP), which with homozygous carrier 786-SS and levels of thrombomodulin "5 ng/ml, SSRI "102 ng/ml, homocysteine 220 μmol/l, SRP "6b mg/l predict the development of osteoarthritis.